Detalles de la búsqueda
1.
Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.
Harm Reduct J
; 20(1): 173, 2023 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38042801
2.
A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder.
Int J Neuropsychopharmacol
; 24(2): 89-96, 2021 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32920647
3.
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 393(10173): 778-790, 2019 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30792007
4.
Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.
Br J Clin Pharmacol
; 83(7): 1476-1498, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28133766
5.
A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
J Pharmacokinet Pharmacodyn
; 44(2): 69-79, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27578330
6.
Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment.
Pharm Res
; 32(2): 654-64, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25186439
7.
An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients.
Clin Drug Investig
; 44(4): 251-260, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38388986
8.
Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.
Pharm Res
; 30(11): 2795-807, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23801085
9.
Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder.
Front Pharmacol
; 13: 1052113, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36467036
10.
Modeling buprenorphine reduction of fentanyl-induced respiratory depression.
JCI Insight
; 7(9)2022 05 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35316224
11.
Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients.
PLoS One
; 17(1): e0256752, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35085249
12.
Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations.
J Antimicrob Chemother
; 66(8): 1798-809, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21653603
13.
Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.
Clin Pharmacol Drug Dev
; 10(9): 1064-1074, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33750027
14.
Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials.
Clin Pharmacokinet
; 60(4): 527-540, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33135125
15.
Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve Individuals.
Clin Pharmacol Ther
; 109(3): 637-645, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32865832
16.
Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
J Pharmacokinet Pharmacodyn
; 36(4): 317-39, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19562469
17.
Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder.
Clin Pharmacol Ther
; 106(3): 576-584, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30801681
18.
Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Drugs R D
; 19(3): 255-265, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31197606
19.
Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.
Clin Pharmacokinet
; 46(3): 221-34, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17328581
20.
Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.
J Clin Pharmacol
; 56(7): 806-15, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26479717